Home/Pipeline/ADSC Therapy for Critical Limb Ischemia

ADSC Therapy for Critical Limb Ischemia

Peripheral Arterial Disease

Pre-clinicalInferred R&D

Key Facts

Indication
Peripheral Arterial Disease
Phase
Pre-clinical
Status
Inferred R&D
Company

About A4Cell

A4Cell is a pioneering regenerative medicine company leveraging adipose-derived stem cells (ADSCs) to develop novel therapies for unmet medical needs. Its core technology platform isolates and expands potent stem cells from fat tissue, offering a minimally invasive and abundant cell source. The company is advancing a pipeline of cell therapy candidates targeting conditions like osteoarthritis, Crohn's disease, and other inflammatory disorders. As a private, research-stage biotech, A4Cell is positioned to capitalize on the growing cell therapy market through strategic development and potential partnerships.

View full company profile